A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation

C. K. Lee, M. de Magalhaes-Silverman, M. Hayashi, A. Schlueter, R. G. Strauss, R. J. Hohl, R. D. Gingrich

Research output: Contribution to journalArticle

Abstract

Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfamide 6 g/m2 and mitoxantrone 12 mg/m2, with arabinosyl cytosine (Ara-C) 2 g/m2, and methylprednisolone 2.0 g. Each cycle of the second and third had cisplatin 90 mg/m2, Ara-C 6 g/m2, methylprednisolone 2.0 g, and escalated doses of ifosfamide from 7.5 g/m2 to 15 g/m2 and mitoxantrone from 16 to 28 mg/m2. Blood stem cells were collected before the second cycle and ≥3 × 106 CD34 cells/kg were infused 2 days after the second and third cycles, respectively. The maximum tolerated doses of ifosfamide and mitoxantrone were 11.25 g/m2 and 16 mg/m2, respectively. Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities. Eleven patients completed therapy. Five patients achieved complete remission and five had partial remission. Nine patients received autologous and four received allogeneic transplants. Currently, six are alive without evidence of disease, with a 3-year survival of 40%. Although preliminary, the regimen suggests acceptable toxicity and significant activity that warrants further study.

Original languageEnglish (US)
Pages (from-to)647-652
Number of pages6
JournalBone Marrow Transplantation
Volume29
Issue number8
DOIs
StatePublished - Jan 1 2002

Fingerprint

Stem Cell Transplantation
Mitoxantrone
Ifosfamide
Lymphoma
Drug Therapy
Cytosine
Methylprednisolone
Transplants
Survival
Maximum Tolerated Dose
Therapeutics
Bacterial Infections
Acute Kidney Injury
Cisplatin
Blood Cells
Stem Cells
Transplantation

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Lee, C. K. ; de Magalhaes-Silverman, M. ; Hayashi, M. ; Schlueter, A. ; Strauss, R. G. ; Hohl, R. J. ; Gingrich, R. D. / A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. In: Bone Marrow Transplantation. 2002 ; Vol. 29, No. 8. pp. 647-652.
@article{5af3f67e52694810a26117ea317dfb77,
title = "A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation",
abstract = "Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfamide 6 g/m2 and mitoxantrone 12 mg/m2, with arabinosyl cytosine (Ara-C) 2 g/m2, and methylprednisolone 2.0 g. Each cycle of the second and third had cisplatin 90 mg/m2, Ara-C 6 g/m2, methylprednisolone 2.0 g, and escalated doses of ifosfamide from 7.5 g/m2 to 15 g/m2 and mitoxantrone from 16 to 28 mg/m2. Blood stem cells were collected before the second cycle and ≥3 × 106 CD34 cells/kg were infused 2 days after the second and third cycles, respectively. The maximum tolerated doses of ifosfamide and mitoxantrone were 11.25 g/m2 and 16 mg/m2, respectively. Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities. Eleven patients completed therapy. Five patients achieved complete remission and five had partial remission. Nine patients received autologous and four received allogeneic transplants. Currently, six are alive without evidence of disease, with a 3-year survival of 40{\%}. Although preliminary, the regimen suggests acceptable toxicity and significant activity that warrants further study.",
author = "Lee, {C. K.} and {de Magalhaes-Silverman}, M. and M. Hayashi and A. Schlueter and Strauss, {R. G.} and Hohl, {R. J.} and Gingrich, {R. D.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1703533",
language = "English (US)",
volume = "29",
pages = "647--652",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. / Lee, C. K.; de Magalhaes-Silverman, M.; Hayashi, M.; Schlueter, A.; Strauss, R. G.; Hohl, R. J.; Gingrich, R. D.

In: Bone Marrow Transplantation, Vol. 29, No. 8, 01.01.2002, p. 647-652.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation

AU - Lee, C. K.

AU - de Magalhaes-Silverman, M.

AU - Hayashi, M.

AU - Schlueter, A.

AU - Strauss, R. G.

AU - Hohl, R. J.

AU - Gingrich, R. D.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfamide 6 g/m2 and mitoxantrone 12 mg/m2, with arabinosyl cytosine (Ara-C) 2 g/m2, and methylprednisolone 2.0 g. Each cycle of the second and third had cisplatin 90 mg/m2, Ara-C 6 g/m2, methylprednisolone 2.0 g, and escalated doses of ifosfamide from 7.5 g/m2 to 15 g/m2 and mitoxantrone from 16 to 28 mg/m2. Blood stem cells were collected before the second cycle and ≥3 × 106 CD34 cells/kg were infused 2 days after the second and third cycles, respectively. The maximum tolerated doses of ifosfamide and mitoxantrone were 11.25 g/m2 and 16 mg/m2, respectively. Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities. Eleven patients completed therapy. Five patients achieved complete remission and five had partial remission. Nine patients received autologous and four received allogeneic transplants. Currently, six are alive without evidence of disease, with a 3-year survival of 40%. Although preliminary, the regimen suggests acceptable toxicity and significant activity that warrants further study.

AB - Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfamide 6 g/m2 and mitoxantrone 12 mg/m2, with arabinosyl cytosine (Ara-C) 2 g/m2, and methylprednisolone 2.0 g. Each cycle of the second and third had cisplatin 90 mg/m2, Ara-C 6 g/m2, methylprednisolone 2.0 g, and escalated doses of ifosfamide from 7.5 g/m2 to 15 g/m2 and mitoxantrone from 16 to 28 mg/m2. Blood stem cells were collected before the second cycle and ≥3 × 106 CD34 cells/kg were infused 2 days after the second and third cycles, respectively. The maximum tolerated doses of ifosfamide and mitoxantrone were 11.25 g/m2 and 16 mg/m2, respectively. Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities. Eleven patients completed therapy. Five patients achieved complete remission and five had partial remission. Nine patients received autologous and four received allogeneic transplants. Currently, six are alive without evidence of disease, with a 3-year survival of 40%. Although preliminary, the regimen suggests acceptable toxicity and significant activity that warrants further study.

UR - http://www.scopus.com/inward/record.url?scp=0036015538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036015538&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703533

DO - 10.1038/sj.bmt.1703533

M3 - Article

C2 - 12180108

AN - SCOPUS:0036015538

VL - 29

SP - 647

EP - 652

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -